Grail (GRAL) Stock Surges 36% Following Positive FDA Advisory Panel Vote on Galleri Test

Grail (GRAL) stock surged 36% after FDA panel voted 7-2 in favor of Galleri cancer test. What's next for approval and revenue growth prospects.

The post Grail (GRAL) Stock Surges 36% Following Positive FDA Advisory Panel Vote on Galleri Test appeared first on Blockonomi.